Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 15/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | TOP2A | P11388 | 1/20 | 0.37 |
| ▸ | TOP2B | Q02880 | 1/20 | 0.37 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12348825 | 0.89 | SMN1; SMN2 (0.41) | THRBSMN1; SMN2TOP2ATOP2B | |
| SCHEMBL13600572 | 0.87 | LMNA (0.34) | THRBSMN1; SMN2 | |
| SCHEMBL9029619 | 0.82 | THRB (0.49) | THRBSMN1; SMN2TOP2ATOP2B | |
| Hydrochloric Acid SCHEMBL9029064 | 0.81 | THRB (0.48) | THRB | |
| SCHEMBL974631 | 0.81 | THRB (0.51) | THRB | |
| SCHEMBL4490796 | 0.80 | SMN1; SMN2 (0.39) | THRBSMN1; SMN2TOP2ATOP2BHRH3 | |
| SCHEMBL30902672 | 0.80 | CXCR4 (0.50) | THRBSMN1; SMN2HRH3 | |
| SCHEMBL30902677 | 0.80 | CXCR4 (0.50) | THRBSMN1; SMN2HRH3 | |
| SCHEMBL10200973 | 0.80 | TOP2A (0.40) | THRBSMN1; SMN2TOP2ATOP2B | |
| SCHEMBL18634073 | 0.79 | THRB (0.53) | THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8580832-B2 | Substituted phenoxy aminothiazolones as estrogen related receptor-α modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2013-11-12 | — | — | US | disclosed |
| US-7632833-B2 | Anticancer agents | MERCK & CO., INC. (US) | 2009-12-15 | — | — | US | disclosed |
| US-20080287414-A1 | Mitotic Kinesin Inhibitors | MERCK & CO., INC. (US) | 2008-11-20 | — | — | US | disclosed |
| US-20080221179-A1 | SUBSTITUTED PHENOXY AMINOTHIAZOLONES as estrogen related receptor-alpha modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287414-A1 | Mitotic Kinesin Inhibitors | KIF5B, KIF2C, KIF18B | THRB 4418/4885SMN1; SMN2 2150/4885TOP2A 126/4885 |
| US-20080221179-A1 | SUBSTITUTED PHENOXY AMINOTHIAZOLONES as estrogen related receptor-alpha modulators | ESR2, ESRRA, ESRRG | THRB 363/4885SMN1; SMN2 3140/4885TOP2A 1194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.